NAV NAVCO Pharmaceuticals Inc.

0.0035USD0.0050 CAD · TSXV0.00%Mkt Cap: 199470 USDP/E: —

NAVCO Pharmaceuticals Inc. develops and commercializes supplemental and therapeutic consumer health and wellness products in the areas of antibacterial and immunity support and infectious disease prevention in Canada. Th…

Key Statistics

Company
Market Cap199.47K USD
Enterprise Value276.65K USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-48.12K USD
Revenue/Share—
Last Price0.0035 USD
Fiscal Year EndSep 2025
MR QuarterJun 2026
Employees—
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINCA63942R1091
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.29
EPS (TTM)0.00 USD
EPS (Forward)—
52W Range
0.00350% of range0.0070
52W High0.0070 USD
52W Low0.0035 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE—
ROA-741.21%
ROIC—
ROCE—
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.18K USD
CapEx (TTM)—
FCF Margin—
FCF Yield1.70%
Net Debt77.18K USD
Net Debt/EBITDA—
Net Debt/FCF22.80
Balance Sheet
Debt/Equity—
Current Ratio0.00
Quick Ratio0.00
Book Value/Sh-0.01 USD
Cash/Share0.00 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.57.07M
Float51.82M
Insiders10.49%
Institutions0.00%
Short Interest
Short Ratio0.1d
Short % Out.0.00%
Shares Short200
Short (prev mo.)512
Technical
SMA 500.0035 (-0.0%)
SMA 2000.0042 (-17.7%)
Beta2.15
S&P 52W Chg12.00%
Avg Vol (30d)773
Avg Vol (10d)0
Technical Indicators
RSI (14)46.9
MACD-0.0000
MACD Signal-0.0000
MACD Hist.+0.0000
BB Upper0.0035 USD
BB Middle0.0035 USD
BB Lower0.0035 USD
BB Width0.00%
ATR (14)0.0000 USD
Vol Ratio (20d)0.00x

About NAVCO Pharmaceuticals (CVE: NAV)

›

NAVCO Pharmaceuticals (CVE: NAV) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector.

The shares were at 0.0050 CAD on 18 November 2026, roughly unchanged over 52 weeks. Its 52-week range is 0.0050 CAD to 0.0100 CAD, and it trades at the bottom of that range.

Its market capitalisation is 285.35K CAD.

NAVCO Pharmaceuticals reports an operating margin of 0.0%.

Its debt exceeds its cash by 110.41K CAD. Its Piotroski F-score is 0 out of 9, a weak reading of its financial health. The next earnings report is expected on 28 January 2027.